ICG in Colon Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTanta University
About this trial
The aim of this study is to evaluate the role of indocyanine green (ICG) injection in fluorescence-guided lymphatic mapping during laparoscopic colon cancer resection. This is a single-center prospective single-arm pilot clinical study that will include at least 25 patients with resectable colon cancer. All enrolled patients will undergo intraoperative subserosal ICG-guided lymphatic mapping before dissection, and intravenous ICG perfusion assessment before anastomosis. The primary goal is to determine the proportion of analyzable pN+ patients in whom all metastatic lymph nodes identified on final histopathology are located within the ICG-mapped lymphatic basin.
Eligibility criteria
Qualifiers
None
Disqualifiers
Emergency surgery (obstruction/perforation with sepsis) requiring urgent operation.
Known allergy or contraindication to ICG (including prior anaphylaxis to ICG; severe hypersensitivity history per anesthesia assessment).
Pregnancy or breastfeeding.
Severe hepatic failure (because ICG clearance is hepatobiliary) or other contraindication determined by anesthesia team.
Trial design
Treatments tested in this trial
- Indocyanine green (ICG) injection for intraoperative lymph node imaging
- Laparoscopic Colon Cancer Resection
Treatment groups
25 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov